477 related articles for article (PubMed ID: 2111051)
1. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1.
Urano T; Sakakibara K; Rydzewski A; Urano S; Takada Y; Takada A
Thromb Haemost; 1990 Feb; 63(1):82-6. PubMed ID: 2111051
[TBL] [Abstract][Full Text] [Related]
2. PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA.
Urano T; Sumiyoshi K; Pietraszek MH; Takada Y; Takada A
Thromb Haemost; 1991 Oct; 66(4):474-8. PubMed ID: 1796399
[TBL] [Abstract][Full Text] [Related]
3. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity].
Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P
Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860
[TBL] [Abstract][Full Text] [Related]
4. Fibrinolytic activity in Chinese patients with diabetes or hyperlipidemia in comparison with healthy controls.
Ho CH; Jap TS
Thromb Haemost; 1991 Jan; 65(1):3-6. PubMed ID: 1902595
[TBL] [Abstract][Full Text] [Related]
5. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
[TBL] [Abstract][Full Text] [Related]
6. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
8. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
Ho CH; Yuan CC; Liu SM
Gynecol Oncol; 1999 Dec; 75(3):397-400. PubMed ID: 10600296
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females.
Koh SC; Yuen R; Viegas OA; Chua SE; Ng BL; Sen DK; Ratnam SS
Thromb Haemost; 1991 Nov; 66(5):581-5. PubMed ID: 1803623
[TBL] [Abstract][Full Text] [Related]
12. Tissue-type plasminogen activator, plasminogen activator inhibitor, and histidine-rich glycoproteins in stressed human newborns.
Corrigan JJ; Jeter MA
Pediatrics; 1992 Jan; 89(1):43-6. PubMed ID: 1728019
[TBL] [Abstract][Full Text] [Related]
13. [Plasminogen tissue activator and plasminogen tissue inhibitor in type II diabetes].
Rość D; Drewniak W; Kotschy M; Graczykowska-Koczorowska A; Raukuć D
Pol Merkur Lekarski; 1997 Jan; 2(7):24-5. PubMed ID: 9296893
[TBL] [Abstract][Full Text] [Related]
14. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
15. Effects of octreotide on epidermal growth factor receptor, tissue plasminogen activator, and plasminogen activator inhibitor during intraperitoneal adhesion formation.
Lai HS; Chen Y; Chang KJ; Chen WJ
J Gastroenterol; 2003; 38(6):555-60. PubMed ID: 12825131
[TBL] [Abstract][Full Text] [Related]
16. Diurnal variation of the fibrinolytic system.
Grimaudo V; Hauert J; Bachmann F; Kruithof EK
Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
[TBL] [Abstract][Full Text] [Related]
17. A new euglobulin clot lysis assay for global fibrinolysis.
Smith AA; Jacobson LJ; Miller BI; Hathaway WE; Manco-Johnson MJ
Thromb Res; 2003; 112(5-6):329-37. PubMed ID: 15041279
[TBL] [Abstract][Full Text] [Related]
18. [Relationship of lipoprotein(a) to fibrinolytic activities in healthy subjects].
Xiong X; Zhao S; Wang Z; Lo L; Huang Q
Hunan Yi Ke Da Xue Xue Bao; 1998; 23(6):555-7. PubMed ID: 10806767
[TBL] [Abstract][Full Text] [Related]
19. [Tissue plasminogen activator, its inhibitor and other parameters of fibrinolysis in blood of patients operated for mild hypertrophy of the prostate].
Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F; Cwiklińska-Jurkowska M
Pol Tyg Lek; 1992 Dec 7-14; 47(49-50):1096-7. PubMed ID: 1284828
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro.
Tanaka A; Suzuki Y; Sugihara K; Kanayama N; Urano T
Life Sci; 2009 Jul; 85(5-6):220-5. PubMed ID: 19500599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
